MarketCap
Facebook
X
Telegram
SpringWorks Therapeutics Current Ratio | SWTX
Annual Current Ratio SpringWorks Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.53 | 7.29 | 8.75 | 15 | 30.1 | 27.7 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.1 | 5.53 | 15.7 |
Quarterly Current Ratio SpringWorks Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.75 | 5.53 | 7.98 | 10.2 | 7.35 | 7.29 | 6.43 | 7.85 | 9.14 | 8.75 | 9.86 | - | 14.1 | 15 | 17.3 | 21.8 | 27.9 | 30.1 | 30.1 | 30.1 | 30.1 | 26.2 | 26.2 | 26.2 | 26.2 | 10 | 10 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.1 | 5.53 | 16.5 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Lipocine
LPCN
|
6.73 | $ 1.59 | -7.85 % | $ 8.66 M |  USA |
 |
PTC Therapeutics
PTCT
|
0.934 | $ 64.12 | -1.4 % | $ 5.1 B | USA |
 |
Seres Therapeutics
MCRB
|
1.47 | $ 1.55 | -8.75 % | $ 13.7 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
1.92 | $ 432.48 | -0.07 % | $ 9.7 B | USA |
 |
CEL-SCI Corporation
CVM
|
2.31 | $ 1.41 | 4.07 % | $ 11.3 M | USA |
 |
Inventiva S.A.
IVA
|
0.527 | $ 3.95 | 2.73 % | $ 236 M |  France |
 |
MeiraGTx Holdings plc
MGTX
|
0.977 | $ 9.62 | 1.37 % | $ 774 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
3.49 | $ 1.86 | -4.62 % | $ 2.44 M | USA |
 |
Eton Pharmaceuticals
ETON
|
1.4 | $ 67.5 | 4.9 % | $ 1.82 B | USA |
 |
IDEAYA Biosciences
IDYA
|
12.8 | $ 31.72 | -0.97 % | $ 2.81 B | USA |
 |
Protalix BioTherapeutics
PLX
|
2.41 | $ 2.86 | 11.28 % | $ 225 M |  Israel |
 |
Lantern Pharma
LTRN
|
2.45 | $ 0.47 | -22.86 % | $ 5.12 M | USA |
 |
Foghorn Therapeutics
FHTX
|
0.646 | $ 1.89 | -7.35 % | $ 119 M | USA |
 |
Ocugen
OCGN
|
0.782 | $ 0.95 | -2.45 % | $ 297 M | USA |
 |
Oncolytics Biotech
ONCY
|
1.42 | $ 0.38 | -5.64 % | $ 36.4 M |  Canada |
 |
Minerva Neurosciences
NERV
|
0.419 | $ 2.47 | -6.08 % | $ 20.9 M | USA |
 |
Kamada Ltd.
KMDA
|
6.58 | $ 8.09 | 4.93 % | $ 466 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
3.36 | $ 169.08 | 0.13 % | $ 16.8 B | USA |
 |
Nanobiotix S.A.
NBTX
|
0.445 | $ 32.8 | 2.4 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
3.36 | $ 0.3 | 1.66 % | $ 239 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
1.94 | $ 7.86 | -2.31 % | $ 1.13 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
2.39 | $ 1.84 | 0.82 % | $ 668 M | USA |
 |
Moleculin Biotech
MBRX
|
3.11 | $ 8.01 | -7.51 % | $ 9.49 M | USA |
 |
Nurix Therapeutics
NRIX
|
4.61 | $ 15.89 | -1.58 % | $ 1.38 B | USA |
 |
Nkarta
NKTX
|
4.4 | $ 1.36 | -14.78 % | $ 101 M | USA |
 |
MacroGenics
MGNX
|
1.28 | $ 2.42 | 3.42 % | $ 153 M | USA |
 |
Protagonist Therapeutics
PTGX
|
12.5 | $ 136.18 | 0.2 % | $ 8.66 B | USA |
|
Nuvation Bio
NUVB
|
2.06 | $ 4.22 | -3.1 % | $ 1.44 B | USA |
 |
Novo Nordisk A/S
NVO
|
1.56 | $ 40.6 | -1.88 % | $ 180 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
8.39 | $ 0.95 | -3.87 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
2.16 | $ 5.97 | -4.78 % | $ 17 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
6.21 | $ 2.46 | -2.96 % | $ 273 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
9.84 | $ 1.22 | -2.8 % | $ 64.1 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
9.72 | $ 7.29 | -1.02 % | $ 634 M | USA |
 |
Kymera Therapeutics
KYMR
|
10.7 | $ 136.45 | -1.74 % | $ 11.5 B | USA |
 |
Oragenics
OGEN
|
5.64 | $ 0.35 | -1.47 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
7.44 | $ 2.8 | -1.75 % | $ 365 M | USA |
 |
Passage Bio
PASG
|
1.22 | $ 3.81 | 11.08 % | $ 12.2 M | USA |
 |
Vaxcyte
PCVX
|
9.47 | $ 66.44 | -1.61 % | $ 9.04 B | USA |
 |
Relay Therapeutics
RLAY
|
11.4 | $ 19.81 | -2.87 % | $ 3.4 B | USA |
 |
Precigen
PGEN
|
1.16 | $ 4.51 | -4.76 % | $ 1.41 B | USA |
 |
Avidity Biosciences
RNA
|
7.27 | $ 8.23 | -1.79 % | $ 1.13 B | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
16 | $ 0.82 | -2.07 % | $ 4.91 M | USA |
 |
Praxis Precision Medicines
PRAX
|
15.7 | $ 337.69 | 1.42 % | $ 7.6 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
1.94 | $ 3.78 | 0.53 % | $ 291 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
1.78 | $ 1.31 | -5.07 % | $ 138 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
5.26 | $ 6.62 | -3.36 % | $ 1.24 B | USA |
 |
PolyPid Ltd.
PYPD
|
24.7 | $ 6.3 | 0.96 % | $ 103 M | Israel |
 |
Outlook Therapeutics
OTLK
|
0.366 | $ 0.46 | -0.84 % | $ 16 M | USA |
 |
uniQure N.V.
QURE
|
1.32 | $ 22.7 | -0.39 % | $ 1.31 B | Niderland |